Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies-Reply

Steve Lu; Hao Wang; Janis M. Taube

doi:10.1001/jamaoncol.2019.5154

Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies-Reply

Steve Lu, Hao Wang, Janis M. Taube

School of Medicine

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	299
Number of pages	1
Journal	JAMA Oncology
Volume	6
Issue number	2
DOIs	https://doi.org/10.1001/jamaoncol.2019.5154
State	Published - Feb 2020

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1001/jamaoncol.2019.5154

Cite this

@article{18f14656532a4ba8864ea6f98c514bd0,

title = "Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies-Reply",

author = "Steve Lu and Hao Wang and Taube, {Janis M.}",

note = "Funding Information: Conflict of Interest Disclosures: Dr Ali reported grants and personal fees from Celgene, personal fees from Bristol-Myers Squibb, grants and personal fees from Aduro Biotech, personal fees from Sanofi, grants and personal fees from Amgen, and grants from Poseida Therapeutics. Dr Overton received funding (grant 5T32CA126607-10) from the National Institutes of Health. Dr Makary receives funding from the Laura and John Arnold Foundation. No other disclosures were reported. 1. Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370-381. doi:10.1016/S1470-2045(18)30072-X 2. Chakraborty R, Majhail NS, Anwer F. Denosumab vs zoledronic acid for bone-targeted therapy in multiple myeloma: what are the unanswered questions? JAMA Oncol. 2019. doi:10.1001/jamaoncol.2019.1598 3. Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P. Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment: a prospective 2-year clinical trial. J Bone Miner Res.2019. doi:10.1002/jbmr.3853 4. West H. Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value. J Clin Oncol. 2011;29(9):1095-1098. doi:10.1200/JCO.2010.33.5596 5. Goldstein DA. Denosumab for bone lesions in multiple myeloma: what is its value? Haematologica. 2018;103(5):753-754. doi:10.3324/haematol.2017.185264 6. Gyawali B, Tessema FA, Jung EH, Kesselheim AS. Assessing the justification, funding, success, and survival outcomes of randomized noninferiority trials of cancer drugs: a systematic review and pooled analysis. JAMA Netw Open. 2019; 2(8):e199570. doi:10.1001/jamanetworkopen.2019.9570",

year = "2020",

month = feb,

doi = "10.1001/jamaoncol.2019.5154",

language = "English (US)",

volume = "6",

pages = "299",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "2",

}

TY - JOUR

T1 - Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies-Reply

AU - Lu, Steve

AU - Wang, Hao

AU - Taube, Janis M.

N1 - Funding Information: Conflict of Interest Disclosures: Dr Ali reported grants and personal fees from Celgene, personal fees from Bristol-Myers Squibb, grants and personal fees from Aduro Biotech, personal fees from Sanofi, grants and personal fees from Amgen, and grants from Poseida Therapeutics. Dr Overton received funding (grant 5T32CA126607-10) from the National Institutes of Health. Dr Makary receives funding from the Laura and John Arnold Foundation. No other disclosures were reported. 1. Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370-381. doi:10.1016/S1470-2045(18)30072-X 2. Chakraborty R, Majhail NS, Anwer F. Denosumab vs zoledronic acid for bone-targeted therapy in multiple myeloma: what are the unanswered questions? JAMA Oncol. 2019. doi:10.1001/jamaoncol.2019.1598 3. Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P. Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment: a prospective 2-year clinical trial. J Bone Miner Res.2019. doi:10.1002/jbmr.3853 4. West H. Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value. J Clin Oncol. 2011;29(9):1095-1098. doi:10.1200/JCO.2010.33.5596 5. Goldstein DA. Denosumab for bone lesions in multiple myeloma: what is its value? Haematologica. 2018;103(5):753-754. doi:10.3324/haematol.2017.185264 6. Gyawali B, Tessema FA, Jung EH, Kesselheim AS. Assessing the justification, funding, success, and survival outcomes of randomized noninferiority trials of cancer drugs: a systematic review and pooled analysis. JAMA Netw Open. 2019; 2(8):e199570. doi:10.1001/jamanetworkopen.2019.9570

PY - 2020/2

Y1 - 2020/2

UR - http://www.scopus.com/inward/record.url?scp=85075836822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075836822&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2019.5154

DO - 10.1001/jamaoncol.2019.5154

M3 - Letter

C2 - 31774476

AN - SCOPUS:85075836822

SN - 2374-2437

VL - 6

SP - 299

JO - JAMA Oncology

JF - JAMA Oncology

IS - 2

ER -

Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies-Reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this